ID: ALA5201671

Max Phase: Preclinical

Molecular Formula: C20H14ClNO3S2

Molecular Weight: 415.92

Representations

Canonical SMILES:  O=C1OC(c2ccsc2)(c2ccccn2)CC(O)=C1Sc1ccccc1Cl

Standard InChI:  InChI=1S/C20H14ClNO3S2/c21-14-5-1-2-6-16(14)27-18-15(23)11-20(25-19(18)24,13-8-10-26-12-13)17-7-3-4-9-22-17/h1-10,12,23H,11H2

Standard InChI Key:  CMOYMCXYHZZXSM-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 415.92

Molecular Weight (Monoisotopic): 415.0104

AlogP: 5.55

#Rotatable Bonds: 4

Polar Surface Area: 59.42

Molecular Species: ACID

HBA: 6

HBD: 1

#RO5 Violations: 1

HBA (Lipinski): 4

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 3.83

CX Basic pKa: 2.93

CX LogP: 4.00

CX LogD: 1.18

Aromatic Rings: 3

Heavy Atoms: 27

QED Weighted: 0.57

Np Likeness Score: -0.85

References

1. Wei B, Robarge K, Labadie SS, Chen J, Corson LB, DiPasquale A, Dragovich PS, Eigenbrot C, Evangelista M, Fauber BP, Hitz A, Hong R, Lai KW, Liu W, Ma S, Malek S, O'Brien T, Pang J, Peterson D, Salphati L, Sampath D, Sideris S, Ultsch M, Xu Z, Yen I, Yu D, Yue Q, Zhou A, Purkey HE..  (2022)  Structure-based optimization of hydroxylactam as potent, cell-active inhibitors of lactate dehydrogenase.,  59  [PMID:35065235] [10.1016/j.bmcl.2022.128576]

2. Wei B, Robarge K, Labadie SS, Chen J, Corson LB, DiPasquale A, Dragovich PS, Eigenbrot C, Evangelista M, Fauber BP, Hitz A, Hong R, Lai KW, Liu W, Ma S, Malek S, O'Brien T, Pang J, Peterson D, Salphati L, Sampath D, Sideris S, Ultsch M, Xu Z, Yen I, Yu D, Yue Q, Zhou A, Purkey HE..  (2022)  Structure-based optimization of hydroxylactam as potent, cell-active inhibitors of lactate dehydrogenase.,  59  [PMID:35065235] [10.1016/j.bmcl.2022.128576]

Source

Source(1):

• Scientific Literature